Clinical Trial Update: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 1/2 trial evaluating CPG 7909 in patients with cutaneous T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• CPG 7909 (CpG 7909)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma, T-Cell, Cutaneous | Phase 1, Phase 2 | Status: COMPLETED